What Is Wharton’s Jelly, and Why Is It Marketed for Joint Injections?
Published November 16, 2026
Protocol: 7 steps in this guide
Wharton’s jelly is the soft, gel-like connective tissue that surrounds the blood vessels in the umbilical cord. In its natural state it contains a matrix of collagen, hyaluronic acid and related molecules, plus mesenchymal stromal cells. Injectable products made from it, according to a 2026 review, “are often presumed or represented to also contain viable MSCs.” The problem is that laboratory tests of commercial products have found few living cells and no colony-forming “stem cells,” and FDA has not approved any Wharton’s jelly product for an orthopedic condition. What reaches the syringe is mostly matrix, not a cell therapy.
Anatomy and matrix of Wharton’s jelly
A 2026 review in the Journal of Translational Medicine, Critical evaluation of compositions and clinical relevance of Wharton’s jelly-derived biologics, describes Wharton’s jelly as “the mucoid connective tissue that surrounds umbilical cord vessels.” It reports that the non-cellular matrix “is composed of collagen fibers, hyaluronic acid, proteoglycans, glycosaminoglycans,” and that the cells in native tissue are mainly multipotent mesenchymal stromal cells. Those cells, and what they are, are covered in what mesenchymal stromal cells are. Wharton’s jelly is not the same as umbilical cord blood, which is the source of FDA-approved transplant products, as explained in what umbilical cord blood is used for in approved stem cell treatments.
Tissue product versus living-cell product
The cells in native tissue are not the same as the cells in a processed, packaged product. The 2026 review’s own laboratory analysis of such products found:
- total cell counts of 3,369 to 111,170 cells per cubic centimeter;
- viability of 0 to 19.1%;
- “only rare viable MSCs.”
It concluded that these products “should be viewed as acellular ECM preparations, comprising negligible MSCs.” A 2021 laboratory study in the American Journal of Sports Medicine (Berger and colleagues) tested five commercial umbilical cord allograft products that claimed to contain viable “stem cells,” three of them from cord tissue. Products from cord tissue had 1% to 22% living cells, and no colony-forming units, the laboratory sign of stromal progenitor cells, were found in any of the five. The authors concluded that clinicians “should remain wary of marketing claims stating otherwise.”
Both sources have interests worth knowing. The 2026 review was supported by companies whose employees or consultants wrote it, TAM Global and Cellular Performance Institute. The 2021 study’s authors include researchers from the research and development department of Regenexx, LLC and from the Centeno-Schultz Clinic. Neither interest changes a cell count, but both are disclosed in the papers.
Processing, donor screening and viability questions
Because the product is donated tissue, three questions matter before any claim about cells: how the tissue was screened and processed, whether the final product has been tested for living cells, and when. How viability is measured, and why a percentage alone does not show what was delivered, is covered in what cell viability means for injectable cell products.
What the evidence would need to show
The 2026 review states that to achieve a measurable effect with MSCs, defined doses are required, “typically ≥10 million MSCs for local delivery,” and that such doses can only be obtained by isolating MSCs from fresh tissue and expanding them in a laboratory. The same review also notes that “there is no universally accepted minimum effective dose of MSCs,” so the 10 million figure is the authors’ summary of doses typically used, not a proven threshold for every product and condition. A product with rare viable cells is still far below the doses typically used in those trials. For a Wharton’s jelly product to support a claim about a joint, it would need human trials of that specific product with a control group, as discussed in what clinical trials show about stem cell injections for knee osteoarthritis.
| Claim in marketing | What to ask | What the 2021 and 2026 laboratory studies found in tested products |
|---|---|---|
| "Contains stem cells" | Has this lot been tested for colony-forming cells? | No colony-forming units in five products; rare viable MSCs |
| "Living cells" | What is the measured viability, and when was it measured? | 0 to 22% in tissue-derived products |
| "Regenerates cartilage" | Which controlled human trial of this product shows that? | Not addressed by laboratory studies |
| "FDA approved" or "FDA registered" | What is the approval document and indication? | See FDA status below |
FDA approval versus registration
FDA’s Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes names Wharton’s jelly among “widely promoted products” and states: “None of these products have been approved for the treatment of any orthopedic condition, such as osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain, or shoulder pain.” That page, current as of April 9, 2024, also says that the only FDA-approved stem cell products are cord blood-derived blood-forming cells. That statement predates FDA’s December 18, 2024 approval of Ryoncil, a donor bone marrow-derived MSC product for a pediatric transplant complication. Ryoncil is not made from Wharton’s jelly and is not approved for joints, so the correction does not help any Wharton’s jelly joint product. FDA’s patient and consumer information on regenerative medicine therapies adds that a firm’s registration with FDA “does not mean the product is legally marketed.”
Contamination and immune risks
Wharton’s jelly products come from a donor, so they carry the questions that apply to any donor tissue: donor screening, infection, and the recipient’s immune response. FDA’s patient information lists safety concerns with illegally marketed regenerative products that include bacterial infections, reactions at the site of administration, and unwanted inflammatory or immune responses to the cells or therapy. These issues are covered in the risks of immune reactions to donor-derived cell products.
Red flags in promotional language
Phrases to question include “millions of stem cells” without a lot-specific test report, “regenerates cartilage” without a controlled human trial, “FDA registered” offered as if it meant approval, and “no risk because it is natural.” Broader warning signs are covered in how to recognize unsupported claims about cartilage regeneration.
Wharton’s jelly is umbilical cord connective tissue whose commercial joint products have been found to contain mostly matrix and few or no living stem cells, and FDA has approved none of them for orthopedic use, so a Wharton’s jelly injection should not be presented as a stem cell treatment for joints.
Cells linked to this one
This guide leads on to
- E2 What Are Mesenchymal Stromal Cells (MSCs)?
- E5 What Is Umbilical Cord Blood Used for in Approved Stem Cell Treatments?
- E9 What Does Cell Viability Mean for Injectable Cell Products?
- F1 What Do Clinical Trials Show About Stem Cell Injections for Knee Osteoarthritis?
- E10 What Are the Risks of Immune Reactions to Donor-Derived Cell Products?
- I7 How Do You Recognize Unsupported Claims About Cartilage Regeneration?
Add a remark